Commonwealth Equity Services
CDTX

Commonwealth Equity Services’s Cidara Therapeutics CDTX Stock Holding History

Commonwealth Equity Services’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-801
Closed -$45K – 3208
2020
Q3 		$45K Buy
801
+100
+14% +$7.06K ﹤0.01% 2952
2020
Q2 		$51K Hold
701
– – ﹤0.01% 2846
2020
Q1 		$34K Buy
701
+124
+21% +$7.43K ﹤0.01% 2715
2019
Q4 		$44K Buy
+577
New +$26.4K ﹤0.01% 2807

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Commonwealth Equity Services's CDTX Position: Q4 2020 in Review

Commonwealth Equity Services sold out of Cidara Therapeutics (CDTX) in Q4 2020, closing a stake of 801 shares — an estimated $45K sold.

Commonwealth Equity Services first reported a position in CDTX in Q4 2019 and held it in 4 quarters. The position peaked at $51K in Q2 2020. 63 funds tracked by Wall St. Rank hold CDTX as of Q4 2020.

  • Commonwealth Equity Services reported no remaining Cidara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Commonwealth Equity Services sold 801 Cidara Therapeutics shares in Q4 2020, an estimated $45K.
  • Commonwealth Equity Services first reported a position in Cidara Therapeutics in Q4 2019 and held it in 4 quarters.
  • Commonwealth Equity Services's Cidara Therapeutics position peaked at $51K in Q2 2020.
  • 63 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2020.

Based on Commonwealth Equity Services's 13F filing for Q4 2020, filed 11 Feb 2021.